OptiBrand Rx’s Post

𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐏𝐞𝐫𝐢𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐎𝐩𝐝𝐢𝐯𝐨® 𝐟𝐨𝐫 𝐑𝐞𝐬𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐍𝐒𝐂𝐋𝐂! The U.S. FDA has approved Opdivo® (nivolumab) with chemotherapy for perioperative treatment of resectable non-small cell lung cancer (NSCLC), offering new hope for patients. This decision follows the success of the CheckMate-77T trial, showing a 42% risk reduction in recurrence and improved event-free survival. Opdivo is now the only PD-1 inhibitor to show significant benefits in both neoadjuvant and perioperative regimens for NSCLC. Bristol Myers Squibb 𝐋𝐞𝐚𝐫𝐧 𝐌𝐨𝐫𝐞:  https://lnkd.in/gtdfCFcS #opdivo #fdaapproval #lungcancer #immunotherapy #oncology #bristolmyerssquibb #cancercare #perioperativetreatment #cancerresearch #checkmate77t #pharma #healthcare #lunghealth #innovation #NSCLC

Getting To Know Your Medications Capecitabine: A potent oral chemotherapy medication used in treating breast, colorectal, and gastric cancers by disrupting cancer cell growth. . . . . . . . . At Getmeds, we understand the importance of accessibility to essential medications. That's why we strive to offer capecitabine at a competitive price, ensuring that cost is not a barrier to effective cancer treatment. Trust Getmeds to provide quality medications at prices that make a difference in your fight against cancer. #cancer #onco #breastcancer #coloncancer #gastriccancer #medicine #treatment #pharma #capecitabine

🚀 FDA Approval Alert! 🚀 FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. This approval is based on the ADRIATIC trial, which demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) for patients treated with durvalumab compared to placebo. This is a major advancement in the treatment of LS-SCLC. 🔗 Read more about the approval #FDAApproval #Imfinzi #CancerTreatment #Oncology #HealthcareInnovation #MedicalResearch #LungCancer #ClinicalTrials #PharmaNews #Safevig solutions sandeep laveti Sneha Akkangire .

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) has announced breakthrough findings on Namodenoson, showing its dual anti-cancer and protective effects in the liver. Research indicates these benefits are linked to increased adiponectin production, a key regulator of anti-inflammatory and metabolic processes. These results will be presented at IDDST-2024 in Shanghai. Namodenoson is currently undergoing Phase III trials for advanced liver cancer and Phase IIb trials for MASH, marking significant progress in liver disease treatment. Learn More about $CANF and sign up for news alerts to stay ahead: https://ow.ly/SI1150Sp9C1 #cancer #cancerresearch #livercancer #namodenoson #medicaltrials #biopharma #mash #liverdisease

Colorectal cancer (CRC) affects millions of Americans every year. With more than 80% of CRCs estimated to be driven by the Wnt/β-catenin signaling pathway, Sapience Therapeutics, Inc. is proud to advance ST316 - a first-in-class Wnt/β-catenin inhibitor with selective targeting capabilities.   We are currently enrolling CRC patients in a Phase 2 Dose Expansion Study across lines of treatment in combination with standard of care. Discover how Sapience Therapeutics is advancing the fight against CRC with ST316: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer

🤒 Chemotherapy's Limited Effectiveness for Pancreatic Cancer 🤒 #shorts Discover why chemotherapy is less effective for pancreatic cancer compared to other cancers, according to an experienced medical expert. #PancreaticCancer #Chemotherapy #CancerTreatment #medicalinsights #CloudHospital You can connect with this clinic through the following link: https://lnkd.in/dMQ3g7DM

Chemotherapy remains a cornerstone in cancer treatment, yet its non-specific targeting of rapidly dividing cells leads to significant gastrointestinal (GI) toxicities, affecting more than 60% of patients on high-dose regimens. This can cause serious complications like oral and intestinal mucositis, resulting in inflammation, ulceration, and pain. Finding new interventions to protect the GI tract without compromising anti-tumor efficacy is crucial to improving patient outcomes and advancing supportive care in oncology. 💡 Frida Ponthan explores a published study by Blume J et al (2023) that leverages an intestinal organoid model to explore strategies for protecting the gut mucosa against chemotherapy, taking advantage of the cell cycle specificity of many cancer drugs. Learn more today 👉 https://lnkd.in/eJuhsNrZ

October is #LiverCancer Awareness Month and we are passionate about bringing you the latest #news, #education & cutting-edge updates 📣 Check out this interview from #ASCO2024 | Choosing efficacious treatment options for #hepatocellularcarcinoma 🎥 Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, discusses how the multitude of treatment options for #hepatocellularcarcinoma (HCC) blurs the line regarding the optimal first-line treatment 🤔 While many patients are receiving #immunotherapies, other regimens also demonstrate promising activity. For instance, the #CheckMate 9DW trial (NCT04039607) revealed that therapeutics such as #sorafenib and #lenvatinib achieved the highest-ever recorded median overall survival (OS) #Atezolizumab plus #bevacizumab is preferred in the first-line setting due to slightly better hazard ratios and statistically significant progression-free survival (PFS) However, #immunotherapies may be chosen for patients with varices or other conditions 🔦 Learn more 👉 https://lnkd.in/eP_XuMNg #LiverCancerAwarenessMonth #VJOncology #Oncologynews

Continuing our quick look at novel therapy alternatives to radical cystectomy for BCG-unresponsive, non-muscle-invasive bladder cancer.   2. Pembrolizumab This is an intravenous checkpoint inhibitor, which was approved by the FDA in 2020 for BCG-unresponsive CIS after presentation of the Keynote-057 clinical trial.   However, at 12 months, the complete response (CR) rate of pembrolizumab is relatively modest, at 19%. Furthermore…“Pembrolizumab represents the most expensive [bladder] salvage option with approximate annual costs of €200,000. Considering a willingness-to-pay threshold of <€50,000, costs of pembrolizumab in our model would have to be reduced by at least 70% to be cost effective, while with pembrolizumab, one QALY is gained at an additional cost of ~€180,000.” (Rieger et al, Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC. BJU International, 2024) Tomorrow: nadofaragene firadenovic-vncg   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   4. Intravesical portuzumab monatox-qqrs (Vicinium)   Vicinium is a recombinant fusion protein that blocks protein synthesis in order to mediate tumour cell death. The FDA denied approval for its use in BCG-unresponsive non-muscle-invasive bladder cancer following a review of the results of a phase 3 single-arm clinical trial. The 3-month complete response rate was 40%, and 52% of patients who responded remained disease-free for 12 months after treatment.   Tomorrow: IL-15 superagonist + BCG   #medicalinnovation #bladdercancer #HIVEC #CombatMedical